10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing
May 19 2020 - 9:00AM
Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM)
announced the two organizations are partnering to pioneer a path
toward the safe return to work by deploying a comprehensive
approach to COVID-19 testing, digital employee symptom screening,
and seamless access to remote and in-person care. 10x Genomics is
the first of One Medical’s more than 7,000 employer customers to
begin executing a multi-pronged, cohort-based return to the
workplace strategy. 10x Genomics added One Medical as a new
healthcare benefit for its employees and began offering voluntary
SARS-CoV-2 PCR tests to monitor for possible infection. As a
part of the testing program, 10x Genomics has also teamed up with
the Translational Genomics Research Institute (TGen), an affiliate
of City of Hope, a non-profit medical institute working on
COVID-19, for clinical testing of nasal swabs.
Deemed an essential business, 10x Genomics has more than 50
academic labs, research institutes and pharmaceutical companies
around the world using its products to make discoveries to
accelerate the development of therapeutics, diagnostics and
vaccines for battling COVID-19. These include the Vanderbilt
Vaccine Center, where researchers are fast-tracking the development
of antibody-based prophylaxis to protect people, particularly first
responders and essential workers, who are at greatest risk of
exposure to COVID-19; Merck, which is working on identifying new
viral targets for potential COVID-19 therapeutics and vaccines; and
multiple labs around the world conducting research into cellular
mechanisms and immune responses to infection, and other aspects of
COVID-19.
To continue delivering its essential products and services, 10x
Genomics partnered with One Medical to deploy its workplace reentry
program, Healthy Together, to quickly operationalize an open-air
testing site for COVID-19 PCR nasal swab collection tests at its
Pleasanton headquarters. The nasal swab tests are sent to TGen’s
COVID-19 clinical laboratory for analysis. 10x Genomics already has
over 150 employees from its R&D, manufacturing and IT groups
enlisted in the program that are being regularly tested in cohorts.
10x Genomics plans to expand the program to cover more than 65
percent of its employee base.
“The pandemic has forced us to be innovative and to forge new
paths to navigate the complexities of the new workplace. We believe
cohort-based testing is a powerful way, along with other
recommended practices, to ensure the safety of employees,” said Ben
Hindson, 10x Genomics Co-founder, President and Chief Scientific
Officer. “In One Medical, we have a partner that shared our
dedication to employee health, applied a methodical science-based
approach to workplace reentry and moved rapidly to operationalize
the effort.”
“10x Genomics is paving the way and modeling the behavior many
employers should look to deploy in their organizations. By
understanding the importance of broad COVID-19 testing among its
employee base, they are showing that cohort-based reentry programs
can work well when individuals are armed with necessary information
about their COVID-19 status and are willing to use that information
to support their employer’s risk mitigation efforts,” said Raj
Behal, MD, MPH, One Medical Chief Quality Officer.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 860 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
740 issued patents and patent applications.
About One Medical One Medical is a
membership-based and technology-powered primary care platform with
seamless digital health and inviting in-office care, convenient to
where people work, shop, live, and click. Our vision is to delight
millions of members with better health and better care while
reducing costs. Our mission is to transform health care for all
through our human-centered, technology-powered model.
Headquartered in San Francisco, 1Life Healthcare, Inc. is the
administrative and managerial services company for the affiliated
One Medical physician-owned professional corporations that deliver
medical services in-office and virtually. 1Life and the One Medical
entities do business under the “One Medical” brand.
Media Contact:Kristina Skinner, One
MedicalDirector of External Communicationspress@onemedical.com(650)
743-5187
10x Genomicsmedia@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024